読み込み中
NASDAQHealthcareMedical - Instruments & Supplies
最新データ
$52.45
−$1.36 · -2.53%
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
前日終値
$52.45
−$1.36 · -2.53%
日中の時刻はETです。市場データは遅延する場合があります。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日中レンジ
現在 $52.45
52週レンジ
現在 $52.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
13
著しい割高
センチメント
63
強気
リスク
57
やや高いリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日中レンジ
現在 $52.45
52週レンジ
現在 $52.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 35万 USD | — | — | 70万 USD | 141.8万 USD |
| 売上原価 | 161万 USD | — | 120.7万 USD | 1194.4万 USD | 196.8万 USD |
| 粗利益 | −126万 USD | — | −120.7万 USD | −1124.4万 USD | −55万 USD |
| 研究開発 | 4472.1万 USD | 3233.6万 USD | 2779.7万 USD | 2083.9万 USD | 2864万 USD |
| 販売・一般管理 | 3202.9万 USD | 2392.1万 USD | 1577.7万 USD | 2597.4万 USD | 3382.4万 USD |
| 営業費用 | 7567.9万 USD | 5625.7万 USD | 4236.7万 USD | 4681.3万 USD | 6246.4万 USD |
| 受取利息 | 421万 USD | 267.2万 USD | 246.4万 USD | — | — |
| 支払利息 | — | — | 110万 USD | 44.8万 USD | 64.6万 USD |
| 減価償却費と償却費 | 107.1万 USD | 117.8万 USD | 120.7万 USD | 135.5万 USD | 114.6万 USD |
| 営業利益 | −7693.9万 USD | −5625.7万 USD | −4357.4万 USD | −5805.7万 USD | −6301.4万 USD |
| 純利益 | −7278.1万 USD | −5358.5万 USD | −4221万 USD | −5850.5万 USD | −6366万 USD |
会社概要が更新されました 2026年10月13日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$53.20
上昇余地（1.43%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
